MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes

Table 1 Clinical and laboratory aspects of the recruited patients for Illumina sequencing in the profiling study

	Sex	Age in yr	AST in IU/L	ALT in IU/L	Total bilirubin in mg/dL	AFP in ng/mL	Albumin in g/dL	Hemoglobin in g/dL	BCLC score
HCC patients
1	Male	65	50.51	33.7	5.18	50.8	3.12	11.3	A
2	Male	55	38.9	44.29	1.92	17.8	3.03	12.2	A
3	Male	57	126.8	194.3	1.91	42.1	2.41	10.4	B
4	Female	59	31.42	26.56	1.38	25.82	2.63	9.4	B
5	Female	57	103.62	39.82	1.95	27.47	2.94	9.6	B
6	Male	57	39.5	43.19	1.81	15.8	2.96	10.2	A
7	Female	53	102.32	37.52	1.94	26.98	2.23	11.1	B
8	Female	60	28.62	21.77	1.2	2365	2.76	9.1	B
9	Male	57	137.9	204.3	1.71	41.7	2.43	10.0	B
10	Male	61	51.38	35.2	5.07	52.1	3.11	111.3	A
LC patients
1	Male	61	39.4	18.8	1.58	26	3.23	9.0
2	Female	59	36.8	59.7	1.51	43	3.45	10.6
3	Female	55	34.9	58.2	1.49	40.9	3.01	10.8
4	Female	52	50.1	52.3	1.58	32.9	2.54	9.2
5	Male	63	78.5	30.9	4.99	7.2	2.46	10.4
6	Female	57	51.6	55.5	1.69	33	2.25	10.5
7	Male	62	77.7	31.7	5.06	7.6	3.75	9.6
8	Male	59	95.4	74.3	1.22	3.6	2.78	10.3
9	Male	53	93.1	71.9	1.19	3.5	2.33	11.2
10	Male	60	38.9	18.2	1.53	25.9	2.54	10.9

AFP: Alpha-fetoprotein; ALT: Alanine amino transferase; AST: Aspartate amino transferase; BCLC: Barcelona clinic liver cancer; HCC: Hepatocellular carcinoma; LC: Liver cirrhosis.